Correlation of HALP Score and Menopause Status With Treatment Response in Hormone Receptor-Positive Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Abstract

Objectives: We aimed to investigate the relationship of neoadjuvant therapy with HALP score, menopausal status and pathological response in patients with luminal A and luminal B breast cancer. Methods: In this retrospective study, the files of patients who applied to Ondokuz Mayıs University Medical Oncology department between January 2016 and January 2023 were scanned and a total of 150 patients, 60 premenopausal and 90 postmenopausal, who received neoadjuvant chemotherapy were included. Results: The median age of premenopausal patients was 40.67±6.35 (min 25-max 50), and postmenopausal patients was 57.67±7.48 (min 43-max 78). There was no relationship between overall survival and menopausal status (p=0.33). HALP score was significant only in postmenopausal patients (p=0.008). There was a significant association with complete pathological response (Miller&Payne 5) and PFS in the entire population (p=0.003). HALP score was lower in patients with PR level below 50% (p=0.039). There was no statistical significant between Ki67 and cerbB2, menopausal status and HALP score (p=0.106, p=0.064, respectively). Conclusion: As a result, we did not detect the relationship between HALP score and pathological response in Luminal A and B patients receiving neoadjuvant therapy.